Data from Covid 19 program expected any day now this could push this low float stock toward $10 fast . One of the CHEAÜEST biotechs on Nasdaq . Market Cap $29 Million /Shares Out 12.3 Million / 2x Phase 3 Assets / 2x NDA (Re)submission expected during next 6-9 months / readout from Covid 19 trial expected during this month if positive Company wil start Phase 2/3 in 1H 2021 / Strong Insider & Institutional Ownership = Low float stock with MASSIVE Upside Potential which could hit $20 and more on Drug approvals and positive results (more infos below) .GL Acer Therapeutics (ACER) Market Cap : $29 Million Cash $7 Million Price $2.40 Shares Out 12.3 Million Latest Presentation https://www.acertx.com/wp-content/uploads/2020/11/acer-public-slides-11-10-2020.pdf These 2 Penny Stocks Are Poised for a Massive Rally, Says Roth Capital.. https://finance.yahoo.com/news/2-penny-stocks-poised-massive-193048728.html
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/acer-therapeutics-reports-q1-2021-200100894.html
Acer Therapeutics plans NDA submission for ACER-001 in Q3 2021 https://seekingalpha.com/news/36998...utm_source=quotemedia.com&utm_medium=referral
ACER 4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness https://www.zacks.com/commentary/17...eakness?cid=CS-ZC-HL-industry_outlook-1741634
